MNOV
MediciNova, Inc.
Price Chart
Latest Quote
$1.32
-0.04 (-2.86%)
Current Price
| Previous Close | $1.36 |
| Open | $1.36 |
| Day High | $1.37 |
| Day Low | $1.32 |
| Volume | 24,904 |
Stock Information
| Shares Outstanding | 49.22M |
| Total Debt | $165K |
| Cash Equivalents | $27.33M |
| Revenue | $597K |
| Net Income | $-11.72M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $65.03M |
| EPS (TTM) | $-0.23 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $39.78M |
| Sales | $597K |
| Income | $-11.72M |
| Book/sh | $0.80 |
| Cash/sh | $0.56 |
| Employees | 6 |
Financial Ratios
| Quick Ratio | 8.91 |
| Current Ratio | 9.09 |
| Debt/Eq | 0.42 |
Returns & Margins
| ROA | -16.97% |
| ROE | -26.24% |
| Gross Margin | 8.03% |
| Operating Margin | -1516.60% |
Ownership
| Insider Ownership | 2.88% |
| Institutional Ownership | 11.04% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -3.07 |
| P/S | 108.99 |
| P/B | 1.65 |
Analyst Data
| Recommendation | none |
| Target Price | $9.00 |
Technical Indicators
| SMA20 | $1.31 |
| SMA50 | $1.37 |
| SMA200 | $1.41 |
| RSI | 50.15 |
| ATR | 0.0506 |
| Shares Float | 42.26M |
| Short Float | 0.36% |
| Short Ratio | 7.23 |
| Volatility | 0.62 |
| Rel Volume | 0.46 |
Performance History
| Week | +0.85% |
| Month | -5.64% |
| Quarter | -8.89% |
| 6 Months | -7.62% |
| YTD | -0.67% |
| Year | +0.85% |
| 3 Years | -43.78% |
| 5 Years | -66.55% |
| 10 Years | -81.13% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $1.32 | 24,904 |
| 2026-06-23 | $1.36 | 254,100 |
| 2026-06-22 | $1.30 | 29,900 |
| 2026-06-18 | $1.32 | 34,800 |
| 2026-06-17 | $1.34 | 17,400 |
| 2026-06-16 | $1.31 | 124,000 |
| 2026-06-15 | $1.25 | 122,100 |
| 2026-06-12 | $1.23 | 100,400 |
| 2026-06-11 | $1.28 | 37,900 |
| 2026-06-10 | $1.27 | 21,900 |
| 2026-06-09 | $1.27 | 15,400 |
| 2026-06-08 | $1.30 | 35,400 |
| 2026-06-05 | $1.31 | 5,400 |
| 2026-06-04 | $1.32 | 8,800 |
| 2026-06-03 | $1.32 | 25,500 |
| 2026-06-02 | $1.34 | 9,500 |
| 2026-06-01 | $1.37 | 42,900 |
| 2026-05-29 | $1.36 | 35,200 |
| 2026-05-28 | $1.37 | 33,500 |
| 2026-05-27 | $1.33 | 95,600 |
| 2026-05-26 | $1.37 | 34,100 |
About MediciNova, Inc.
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
đ° Latest News
We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth
Simply Wall St. âĸ 2026-05-16T12:28:46Z
Super Micro downgraded, MongoDB upgraded: Wall Street's top analyst calls
The Fly âĸ 2026-03-23T13:44:20Z
MediciNova: Q4 Earnings Snapshot
Associated Press Finance âĸ 2026-02-20T11:40:18ZATA Creativity Global Among 3 Promising Penny Stocks
Simply Wall St. âĸ 2026-01-20T12:05:20Z
MediciNova: Q3 Earnings Snapshot
Associated Press Finance âĸ 2025-11-12T22:22:39Z3 Penny Stocks With Market Caps Over $80M To Consider
Simply Wall St. âĸ 2025-11-03T12:05:06Z
MediciNova compounds demonstrate novel therapeutic approach for Atherosclerosis
TipRanks âĸ 2025-11-01T00:55:15Z
MediciNova concludes subject enrolment in trial of MN-166
Clinical Trials Arena âĸ 2025-09-23T11:13:16Z
MediciNova: Q2 Earnings Snapshot
Associated Press Finance âĸ 2025-08-14T21:30:25Z3 Penny Stocks With Market Caps Larger Than $10M To Watch
Simply Wall St. âĸ 2025-07-31T18:05:09Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $378,606 | $0 | - | - |
| Cost Of Revenue | $378,606 | $0 | - | - |
| Total Revenue | $409,657 | $0 | $1,000,000 | $0 |
| Operating Revenue | $409,657 | $0 | $1,000,000 | $0 |
| Expenses | ||||
| Total Expenses | $13,692,659 | $12,675,331 | $10,900,265 | $14,628,649 |
| Other Income Expense | $-12,753 | $-39,485 | $-502,869 | $-247,285 |
| Other Non Operating Income Expenses | $-12,753 | $-39,485 | $-502,869 | $-247,285 |
| Net Non Operating Interest Income Expense | $1,303,792 | $1,670,804 | $1,834,665 | $809,673 |
| Operating Expense | $13,314,053 | $12,675,331 | $10,900,265 | $14,628,649 |
| General And Administrative Expense | $6,159,205 | $5,480,600 | $5,242,370 | $5,484,857 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-11,997,957 | $-11,049,549 | $-8,571,516 | $-14,069,083 |
| Net Interest Income | $1,303,792 | $1,670,804 | $1,834,665 | $809,673 |
| Interest Income | $1,303,792 | $1,670,804 | $1,834,665 | $809,673 |
| Normalized Income | $-11,997,957 | $-11,049,549 | $-8,571,516 | $-14,069,083 |
| Net Income From Continuing And Discontinued Operation | $-11,997,957 | $-11,049,549 | $-8,571,516 | $-14,069,083 |
| Total Operating Income As Reported | $-13,283,002 | $-12,675,331 | $-9,900,265 | $-14,628,649 |
| Net Income Common Stockholders | $-11,997,957 | $-11,049,549 | $-8,571,516 | $-14,069,083 |
| Net Income | $-11,997,957 | $-11,049,549 | $-8,571,516 | $-14,069,083 |
| Net Income Including Noncontrolling Interests | $-11,997,957 | $-11,049,549 | $-8,571,516 | $-14,069,083 |
| Net Income Continuous Operations | $-11,997,957 | $-11,049,549 | $-8,571,516 | $-14,069,083 |
| Pretax Income | $-11,991,963 | $-11,044,012 | $-8,568,469 | $-14,066,261 |
| Interest Income Non Operating | $1,303,792 | $1,670,804 | $1,834,665 | $809,673 |
| Operating Income | $-13,283,002 | $-12,675,331 | $-9,900,265 | $-14,628,649 |
| Gross Profit | $31,051 | $0 | - | - |
| Per Share | ||||
| Diluted EPS | $-0.24 | $-0.23 | $-0.17 | $-0.29 |
| Basic EPS | $-0.24 | $-0.23 | $-0.17 | $-0.29 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-13,262,903 | $-12,654,254 | $-9,879,970 | $-14,610,942 |
| Reconciled Depreciation | $20,099 | $21,077 | $20,295 | $17,707 |
| EBITDA (Bullshit earnings) | $-13,262,903 | $-12,654,254 | $-9,879,970 | $-14,610,942 |
| EBIT | $-13,283,002 | $-12,675,331 | $-9,900,265 | $-14,628,649 |
| Diluted Average Shares | $49,063,438 | $49,046,246 | $49,046,246 | $49,045,342 |
| Basic Average Shares | $49,063,438 | $49,046,246 | $49,046,246 | $49,045,342 |
| Diluted NI Availto Com Stockholders | $-11,997,957 | $-11,049,549 | $-8,571,516 | $-14,069,083 |
| Tax Provision | $5,994 | $5,537 | $3,047 | $2,822 |
| Research And Development | $7,154,848 | $7,194,731 | $5,657,895 | $9,143,792 |
| Selling General And Administration | $6,159,205 | $5,480,600 | $5,242,370 | $5,484,857 |
| Other Gand A | $6,159,205 | $5,480,600 | $5,242,370 | $5,484,857 |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $27,186,441 | $38,103,311 | $47,978,184 | $55,841,795 |
| Total Assets | $45,603,109 | $55,875,926 | $66,269,977 | $74,154,905 |
| Total Non Current Assets | $14,611,805 | $14,801,647 | $15,095,597 | $15,167,796 |
| Other Non Current Assets | $18,996 | $18,996 | $74,151 | $92,792 |
| Goodwill And Other Intangible Assets | $14,400,240 | $14,400,240 | $14,400,240 | $14,400,240 |
| Other Intangible Assets | $4,800,000 | $4,800,000 | $4,800,000 | $4,800,000 |
| Current Assets | $30,991,304 | $41,074,279 | $51,174,380 | $58,987,109 |
| Other Current Assets | $184,827 | $714,541 | $174,938 | $499,403 |
| Cash Cash Equivalents And Short Term Investments | $30,806,477 | $40,359,738 | $50,999,442 | $58,487,706 |
| Cash And Cash Equivalents | $30,806,477 | $40,359,738 | $50,999,442 | $18,505,493 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $194,331 | $193,769 | $215,926 | $157,505 |
| Current Debt And Capital Lease Obligation | $194,331 | $193,769 | $215,926 | $157,505 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $4,016,428 | $3,372,375 | $3,891,553 | $3,912,870 |
| Total Non Current Liabilities Net Minority Interest | $218,921 | $413,252 | $612,452 | $725,411 |
| Other Non Current Liabilities | $17,129 | $211,460 | $410,660 | $523,619 |
| Non Current Deferred Liabilities | $201,792 | $201,792 | $201,792 | $201,792 |
| Non Current Deferred Taxes Liabilities | $201,792 | $201,792 | $201,792 | $201,792 |
| Current Liabilities | $3,797,507 | $2,959,123 | $3,279,101 | $3,187,459 |
| Other Current Liabilities | $146,540 | $126,832 | $164,375 | $184,100 |
| Current Deferred Liabilities | $370,160 | $0 | - | - |
| Payables And Accrued Expenses | $2,261,947 | $1,852,573 | $2,074,410 | $1,925,688 |
| Payables | $624,995 | $1,102,494 | $1,003,937 | $424,646 |
| Accounts Payable | $624,995 | $1,102,494 | $1,003,937 | $424,646 |
| Equity | ||||
| Common Stock Equity | $41,586,681 | $52,503,551 | $62,378,424 | $70,242,035 |
| Total Equity Gross Minority Interest | $41,586,681 | $52,503,551 | $62,378,424 | $70,242,035 |
| Stockholders Equity | $41,586,681 | $52,503,551 | $62,378,424 | $70,242,035 |
| Gains Losses Not Affecting Retained Earnings | $-127,180 | $-135,154 | $-118,090 | $-115,285 |
| Other Equity Adjustments | $-127,180 | $-135,154 | $-118,090 | $-115,285 |
| Retained Earnings | $-438,749,199 | $-426,751,242 | $-415,701,693 | $-407,130,177 |
| Other | ||||
| Ordinary Shares Number | $49,221,246 | $49,046,246 | $49,046,246 | $49,046,246 |
| Share Issued | $49,221,246 | $49,046,246 | $49,046,246 | $49,046,246 |
| Invested Capital | $41,586,681 | $52,503,551 | $62,378,424 | $70,242,035 |
| Working Capital | $27,193,797 | $38,115,156 | $47,895,279 | $55,799,650 |
| Capital Lease Obligations | $194,331 | $193,769 | $215,926 | $157,505 |
| Total Capitalization | $41,586,681 | $52,503,551 | $62,378,424 | $70,242,035 |
| Additional Paid In Capital | $480,413,839 | $479,340,901 | $478,149,161 | $477,438,451 |
| Capital Stock | $49,221 | $49,046 | $49,046 | $49,046 |
| Common Stock | $49,221 | $49,046 | $49,046 | $49,046 |
| Current Deferred Revenue | $370,160 | $0 | - | - |
| Current Capital Lease Obligation | $194,331 | $193,769 | $215,926 | $157,505 |
| Pensionand Other Post Retirement Benefit Plans Current | $824,529 | $785,949 | $824,390 | $920,166 |
| Current Accrued Expenses | $1,636,952 | $750,079 | $1,070,473 | $1,501,042 |
| Goodwill | $9,600,240 | $9,600,240 | $9,600,240 | $9,600,240 |
| Net PPE | $192,569 | $382,411 | $621,206 | $674,764 |
| Accumulated Depreciation | $-422,809 | $-402,734 | $-443,513 | $-432,800 |
| Gross PPE | $615,378 | $785,145 | $1,064,719 | $1,107,564 |
| Other Properties | $184,229 | $356,904 | $575,406 | $629,495 |
| Machinery Furniture Equipment | $431,149 | $428,241 | $476,734 | $464,537 |
| Leases | - | $0 | $12,579 | $13,532 |
| Properties | - | $0 | $0 | $0 |
| Treasury Shares Number | - | - | $0 | - |
| Other Short Term Investments | - | - | $0 | $39,982,213 |
| Non Current Deferred Revenue | - | - | - | - |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-9,812,960 | $-10,643,859 | $-7,452,337 | $-12,916,573 |
| Operating Activities | ||||
| Operating Cash Flow | $-9,810,061 | $-10,642,964 | $-7,431,038 | $-12,911,563 |
| Cash Flow From Continuing Operating Activities | $-9,810,061 | $-10,642,964 | $-7,431,038 | $-12,911,563 |
| Operating Gains Losses | - | $-198 | $449,375 | $122,475 |
| Investing Activities | ||||
| Capital Expenditure | $-2,899 | $-895 | $-21,299 | $-5,010 |
| Investing Cash Flow | $-2,899 | $-697 | $39,907,716 | $-40,005,010 |
| Cash Flow From Continuing Investing Activities | $-2,899 | $-697 | $39,907,716 | $-40,005,010 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $244,018 | $0 | $0 | $7,920 |
| Financing Cash Flow | $244,018 | $0 | $0 | $7,920 |
| Cash Flow From Continuing Financing Activities | $244,018 | $0 | $0 | $7,920 |
| Net Common Stock Issuance | $244,018 | $0 | $0 | $7,920 |
| Common Stock Issuance | $244,018 | $0 | $0 | $7,920 |
| Net Other Financing Charges | - | - | - | - |
| Other | ||||
| Income Tax Paid Supplemental Data | $5,619 | $5,042 | $3,667 | $0 |
| End Cash Position | $30,806,477 | $40,359,738 | $50,999,442 | $18,505,493 |
| Beginning Cash Position | $40,359,738 | $50,999,442 | $18,505,493 | $71,430,954 |
| Effect Of Exchange Rate Changes | $15,681 | $3,957 | $17,271 | $-16,808 |
| Changes In Cash | $-9,568,942 | $-10,643,661 | $32,476,678 | $-52,908,653 |
| Net PPE Purchase And Sale | $-2,899 | $-697 | $-21,299 | $-5,010 |
| Sale Of PPE | $0 | $198 | $0 | - |
| Purchase Of PPE | $-2,899 | $-895 | $-21,299 | $-5,010 |
| Change In Working Capital | $1,165,021 | $-979,556 | $111,986 | $334,100 |
| Change In Other Working Capital | $370,160 | - | - | - |
| Change In Other Current Liabilities | $-195,010 | $-176,204 | $-194,880 | $-145,515 |
| Change In Payables And Accrued Expense | $459,871 | $-312,347 | $19,238 | $329,010 |
| Change In Payable | $459,871 | $-312,347 | $19,238 | $329,010 |
| Change In Account Payable | $459,871 | $-312,347 | $19,238 | $329,010 |
| Change In Prepaid Assets | $530,000 | $-491,005 | $287,628 | $150,605 |
| Other Non Cash Items | $173,681 | $173,522 | $-151,888 | $40,716 |
| Stock Based Compensation | $829,095 | $1,191,740 | $710,710 | $642,522 |
| Depreciation Amortization Depletion | $20,099 | $21,077 | $20,295 | $17,707 |
| Depreciation And Amortization | $20,099 | $21,077 | $20,295 | $17,707 |
| Gain Loss On Sale Of PPE | $0 | $-198 | $472 | $0 |
| Net Income From Continuing Operations | $-11,997,957 | $-11,049,549 | $-8,571,516 | $-14,069,083 |
| Net Investment Purchase And Sale | - | $0 | $39,929,015 | $-40,000,000 |
| Sale Of Investment | - | $0 | $39,929,015 | $19,877,526 |
| Purchase Of Investment | - | - | $0 | $-59,877,526 |
| Gain Loss On Investment Securities | - | - | $448,903 | $122,475 |
| Proceeds From Stock Option Exercised | - | - | - | $0 |
Fetched: 2026-06-23